大脑中动脉M2段闭塞:直接血管内治疗与桥接治疗的比较——MR CLEAN登记研究
主要结局为90天改良Rankin量表(mRS)评分,采用逆概率治疗加权调整基线失衡后,桥接治疗与单纯血管内治疗相比显著降低残疾(调整后共同优势比1.52,95%CI 1.04-2.21;P=0.03)。结论提示对于M2段闭塞患者,桥接治疗可能带来更优的功能结局。
要点
- 桥接治疗与90天mRS评分改善显著相关(aOR 1.52,95%CI 1.04-2.21;P=0.03)。
- 二分类功能结局和死亡率数值上倾向桥接治疗,但差异无统计学意义。
- 再通率和症状性颅内出血数值上倾向单纯EVT,但差异无统计学意义。
核心结论
- 对于大脑中动脉M2段闭塞患者,桥接治疗可能较单纯血管内治疗获得更优的功能结局。
主要发现
- 逆概率治疗加权分析显示,桥接治疗与90天mRS评分改善显著相关(调整后共同优势比1.52,95%CI 1.04-2.21;P=0.03)。
- mRS 0-1分比例桥接组38.9% vs 单纯EVT组29.7%(aOR 1.40,95%CI 0.85-2.30;P=0.19),差异无统计学意义。
- mRS 0-2分比例桥接组57.8% vs 单纯EVT组46.5%(aOR 1.42,95%CI 0.88-2.29;P=0.15),差异无统计学意义。
- mRS 0-3分比例桥接组73.2% vs 单纯EVT组59.4%(aOR 1.54,95%CI 0.94-2.51;P=0.09),差异无统计学意义。
- 90天死亡率桥接组17.2% vs 单纯EVT组25.8%(aOR 0.83,95%CI 0.47-1.45;P=0.51),差异无统计学意义。
关键数值与推荐
- 主要结局为90天mRS评分,采用序数逻辑回归分析。
- 二分类mRS评分(0-1、0-2、0-3)、90天死亡和症状性颅内出血为次要结局。
- 再通率采用扩展脑梗死溶栓评分评估,症状性颅内出血和再通率差异均无统计学意义(P>0.05)。
临床怎么用
- 对于大脑中动脉M2段闭塞且适合静脉溶栓的患者,桥接治疗可能较单纯血管内治疗改善功能结局。
- 治疗决策需个体化权衡桥接治疗的潜在功能获益与出血风险。
局限性
- 研究为登记研究,非随机对照设计,存在选择偏倚和混杂可能。
- 样本量有限,二分类结局和安全性结局的差异未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal strategy for managing M2 segment occlusions of the middle cerebral artery, whether with direct endovascular treatment (EVT) or bridging therapy with intravenous thrombolysis (IVT) before EVT, remains unclear. This study aimed to evaluate the effectiveness and safety of both approaches. METHODS: Patients with M2 segment occlusions of the middle cerebral artery, treated between March 2014 and December 2018, were identified from the MR CLEAN Registry (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands), a prospective, nationwide, multicenter registry of patients with acute ischemic stroke who underwent endovascular treatment during that period. They were divided into 2 groups: those who received IVT followed by EVT, and those who received EVT alone. Primary outcomes included functional outcomes at 90 days, assessed by ordinal logistic regression analysis of modified Rankin Scale (mRS) scores. Secondary outcomes included recanalization rates measured by extended Thrombolysis in Cerebral Infarction scores, dichotomized mRS scores (0-1, 0-2, and 0-3), death at 90 days, and symptomatic intracranial hemorrhage. All analyses were performed using both unadjusted and adjusted multivariable approaches, with adjustment achieved through inverse probability of treatment weighting to account for baseline imbalances, including age, baseline National Institutes of Health Stroke Scale score, prior stroke, history of atrial fibrillation, anticoagulant use, and transfer status. RESULTS: A total of 539 patients with M2 occlusions were included in the analysis: 377 received IVT+EVT and 162 received EVT alone. The median age was significantly lower in the IVT+EVT group compared with the EVT-alone group (71 [61-79] versus 74 [65-81]; P=0.01), whereas the proportion of male patients was similar between groups (55.2% versus 51.9%; P=0.15). At 90 days, inverse probability of treatment weighting analysis showed that IVT+EVT was significantly associated with reduced disability compared with EVT alone (adjusted common odds ratio for mRS score, 1.52 [95% CI, 1.04-2.21]; P=0.03). Dichotomized functional outcomes and mortality were numerically in favor of IVT+EVT, with higher rates of mRS score of 0 to 1 (38.9% versus 29.7%, aOR, 1.40 [95% CI, 0.85-2.30]; P=0.19), mRS score of 0 to 2 (57.8% versus 46.5%; aOR, 1.42 [95% CI, 0.88-2.29]; P=0.15), and mRS score of 0 to 3 (73.2% versus 59.4%, aOR, 1.54 [95% CI, 0.94-2.51]; P=0.09), as well as lower 90-day mortality (17.2% versus 25.8%; aOR, 0.83 [95% CI, 0.47-1.45]; P=0.51). In contrast, recanalization rates and symptomatic intracranial hemorrhage were numerically in favor of EVT alone, but all these differences were not statistically significant (P>0.05). CONCLUSIONS: Bridging therapy may yield superior functional outcomes compared with EVT alone for patients with the middle cerebral artery-M2 occlusions.
引用
- Doheim MF, Knapen RRMM, Staals J, et al. Direct Endovascular Versus Bridging Therapy in M2 Segment Occlusion of Middle Cerebral Artery: A MR CLEAN Registry Study. Stroke. 2025. PMID: 40878683. doi:10.1161/STROKEAHA.125.051967
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。